Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13591144 | 0.93 | CYP3A4 (0.49) | CYP3A4KCNH2HRH3KDM4EALDH1A1 | |
| SCHEMBL13591257 | 0.93 | CYP3A4 (0.48) | CYP3A4KCNH2HRH3KDM4EALDH1A1 | |
| SCHEMBL13591265 | 0.92 | CYP3A4 (0.48) | CYP3A4KCNH2HRH3KDM4EALDH1A1 | |
| SCHEMBL14091094 | 0.91 | CYP3A4 (0.48) | CYP3A4KCNH2HRH3 | |
| SCHEMBL14091014 | 0.91 | CYP3A4 (0.46) | CYP3A4KCNH2HRH3 | |
| SCHEMBL13591141 | 0.90 | CYP3A4 (0.51) | CYP3A4KCNH2HRH3 | |
| SCHEMBL13591161 | 0.90 | CYP3A4 (0.50) | CYP3A4KCNH2HRH3 | |
| SCHEMBL13591159 | 0.89 | CYP3A4 (0.47) | CYP3A4KCNH2HRH3 | |
| SCHEMBL14091100 | 0.89 | CYP3A4 (0.47) | CYP3A4KCNH2HRH3 | |
| SCHEMBL14469149 | 0.87 | CYP3A4 (0.51) | CYP3A4KDM4EALDH1A1MAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1896453-B1 | CARBON-LINKED SUBSTITUTED PIPERIDINES AND DERIVATIVES THEREOF USEFUL AS HISTAMINE H3 ANTAGONISTS | SCHERING CORP (US) | 2009-12-02 | — | — | EP | disclosed |
| US-7408066-B2 | Carbon-linked substituted piperidines and derivatives thereof useful as histamine H3 antagonists | SCHERING CORPROATION (US) | 2008-08-05 | — | — | US | disclosed |
| US-7408066-B2 | Carbon-linked substituted piperidines and derivatives thereof useful as histamine H3 antagonists | SCHERING CORPROATION (US) | 2008-08-05 | — | — | US | disclosed |
| WO-2007075555-A2 | COMBINATION OF AN H3 ANTAGONIST/INVERSE AGONIST AND AN APPETITE SUPPRESSANT | SCHERING CORPORATION (US) | 2007-07-05 | — | — | WO | disclosed |
| US-20070010513-A1 | Carbon-linked substituted piperidines and derivatives thereof useful as histamine H3 antagonists | SCHERING CORPORATION | 2007-01-11 | — | — | US | disclosed |
| US-20070010513-A1 | Carbon-linked substituted piperidines and derivatives thereof useful as histamine H3 antagonists | SCHERING CORPORATION | 2007-01-11 | — | — | US | disclosed |
| WO-2007002057-A1 | CARBON-LINKED SUBSTITUTED PIPERIDINES AND DERIVATIVES THEREOF USEFUL AS HISTAMINE H3 ANTAGONISTS | SCHERING CORPORATION (US) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010513-A1 | Carbon-linked substituted piperidines and derivatives thereof useful as histamine H3 antagonists | HRH3, HRH4, CHRM1 | CYP3A4 907/4885KCNH2 1376/4885HRH3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.